Get the Weekly Intelligence Brief — top committee picks every Sunday.
ALGN · NASDAQ · STOCK

Align Technology (ALGN) Stock Analysis

Healthcare Updated October 14, 2026
$147.76
52W $126.33 – $200.44
61/100
$10.28B
24.9
1.67
AI Committee Verdict
Buy
61/100
Conviction: Contested · 50% agreement · 6 analysts
+31.2%
-1.8%
17.26:1
Contested

Is ALGN Bullish or Bearish?

Bullish. Innellis AI committee rates Align Technology (ALGN) Buy with a composite score of 61/100 , based on 6 analysts with 50% agreement. Last updated October 14, 2026.

What Would Change This View

Upgrade to Strong Buy
Requires a committee score of 75.0 — +13.54 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Watch
Requires the score to fall below 55.0 — -6.46 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The committee is genuinely divided. Risk Analyst sees a compelling case — low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock. Portfolio Manager remains cautious — 2 existing position pair(s) are highly correlated already. This disagreement is itself the signal — the setup is not clean in either direction.

Bull & Bear Case

Bull Case
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
  • MACD histogram positive -- bullish momentum — Technical
  • Weekly trend (downtrend) confirms the daily trend -- multi-timeframe agreement — Technical
  • Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock — Risk
Bear Case
  • EPS declining -2.5% YoY despite any revenue growth — Growth
  • Price structure making lower highs and lower lows — Technical
  • Trend and market structure agree -- coherent bearish picture — Technical
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of October 14, 2026
Overall Committee Score
61/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 23%
of 192 Healthcare peers
Value Analyst bullish
62 / 100 · Moderate confidence
Classic value case: cheap on multiples with earnings power to back it up
Growth Analyst neutral
48 / 100 · High confidence
Moderate growth -- present but not remarkable
+ Quarter-over-quarter growth rate is ACCELERATING, not just positive
− EPS declining -2.5% YoY despite any revenue growth
Technical Analyst neutral
56 / 100 · High confidence
Mixed or range-bound price action
+ MACD histogram positive -- bullish momentum
− Price structure making lower highs and lower lows
Risk Analyst bullish
80 / 100 · Low confidence
Risk profile is manageable -- leverage, volatility, and event exposure all look contained
+ Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock
Macro Analyst bullish
65 / 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst neutral
58 / 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager bearish
35 / 100 · Low confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− 2 existing position pair(s) are highly correlated already
Open Full Terminal →

Investment Thesis Evolution

Committee score moved marginally from 64.0 to 61.5.

Analyst-level changes:
  • Macro Analyst: score 80->65 (-15).
  • Portfolio Manager: score 30->35 (+5).

Comparing 2026-10-13 to 2026-10-14 (1 day apart).

Technical Analysis

RSI (14)
52.4
Neutral
MACD Histogram
0.672
Bullish Momentum
Trend Direction
Downtrend
Weekly: Downtrend
Market Structure
Lh Ll
Support
$141.84
Resistance
$189.59
Bollinger %B
0.47
Inside Bands
Price vs Moving Averages
EMA 9
$142.99 Above
EMA 21
$145.63 Above
EMA 50
$153.10 Below
EMA 200
$164.72 Below

Fundamental Analysis

Valuation
82
Growth
58
Profitability
67
Financial Health
75
Cash Flow
70
Valuation
P/E Ratio 24.9×
P/B Ratio 2.42×
PEG Ratio -8.69
Dividend Yield 0.00%
52W High $200.44
52W Low $126.33
Quality & Growth
ROE 1013.4%
ROA 658.3%
Gross Margin 6647.9%
Operating Margin 1333.1%
Revenue Growth YoY —
Debt / Equity 0.03
AI Fundamental Assessment
P/E ratio of 24.9 (inexpensive relative to a 15-40x range); Price-to-book of 2.4x; PEG ratio of -8.7 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 10.1%; Return on assets of 6.6%; Net margin of 10.0%; Gross margin of 66.5%; Current ratio of 1.40 (tight short-term liquidity); Debt-to-equity of 0.03; Free cash flow per share is positive (10.58); Most recent quarter missed estimates by 0.9%; EPS growth accelerating (-21.6% -> +2.3% QoQ); Average YoY EPS growth of 6.0%; Analyst estimates falling over recent quarters
Get the Full ALGN Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime